Long-term safety study of biosimilar anti-TNF initiated

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Long-term safety study of biosimilar anti-TNF initiated

Biosimilars/News | Posted 18/04/2014 0 Post your comment

The Polish Society of Gastroenterology is starting an observational trial to study the long-term safety of anti-tumour necrosis factor (TNF) antibodies, including biosimilars, in the treatment of inflammatory bowel disease (IBD), according to ClinicalTrials.gov.

The European Medicines Agency (EMA) approved its first monoclonal antibody (mAb) biosimilar infliximab (Inflectra, Remsima) in July 2013 for the same indications as the originator product Remicade [1]. The indications cover a range of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. These indications go beyond those studied for the biosimilar [2].

These approvals have prompted the Polish Society of Gastroenterology to initiate a study to evaluate the safety of anti-tumour necrosis factor (TNF) antibodies, including biosimilars, in the treatment of IBD over a two-year period. Data on response, tolerability and safety of anti-TNF and on concomitant treatment will be collected.

The trial is a prospective, multicentre, observational cohort study. The main objective of the study is to assess the safety of treatment with anti-TNF monoclonal antibodies in IBD patients in Poland. The primary outcome of the trial is the frequency of adverse events on induction of remission and maintenance treatment using anti-TNFs (including biosimilars) in a cohort of IBD patients over a period of up to three years. The trial will include 400 paediatric and adult patients, in whom anti-TNF treatment is started for Crohn’s disease, ulcerative colitis or indeterminate colitis, financed by the National Health Care System.

The trial will include the majority of IBD centres in Poland, including paediatric and adult, academic and regional. It is expected to last two years and is expected to be completed in December 2016.

References
1. Thorpe R, Wadhwa M. Biosimilar monoclonal antibodies approved for use in the EU. Generics and Biosimilars Initiative Journal (GaBI Journal). 2014;3(1):9. doi:10.5639/gabij.2014.0301.004
2. ECCO survey highlights lack of confidence in biosimilars. Generics and Biosimilars Initiative Journal (GaBI Journal). 2014;3(3):154. doi:10.5639/gabij.2014.0303.034

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: EU Clinical Trials Register